TORONTO–(BUSINESS WIRE)–Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (Cybin or the Firm), a clinical-stage breakthrough neuropsychiatry firm dedicated to revolutionizing psychological healthcare by creating new and modern next-generation remedy choices, is happy to announce that Amir Inamdar, Cybin’s Chief Medical Officer, will take part in a panel dialogue on the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Summit going down nearly on September 26, 2024.
The panel dialogue, titled Development in Psychedelic Therapies for Neuropsychiatry, will probably be webcast dwell on Thursday, September 26, 2024, at 10:00 a.m. ET. To hearken to the occasion, please click on right here to entry the webcast. The archived webcast will even be accessible on the Firm’s investor relations web site on the Occasions & Displays web page.
About Cybin
Cybin is a late-stage breakthrough neuropsychiatry firm dedicated to revolutionizing psychological healthcare by creating new and modern next-generation remedy choices to handle the massive unmet want for individuals who endure from psychological well being situations.
With business main proof-of-concept knowledge, Cybin is working to alter the psychological well being remedy panorama by means of the introduction of intermittent remedies that present lengthy lasting outcomes. The Firm is presently creating CYB003, a proprietary deuterated psilocin program, about to enter Part 3 research for the adjunctive remedy of main depressive dysfunction and CYB004, a proprietary deuterated DMT program in a Part 2 examine for generalized anxiousness dysfunction. The corporate additionally has a analysis pipeline of investigational, 5-HT-receptor targeted compounds.
Based in 2019, Cybin is operational in Canada, the USA, the UK, the Netherlands and Eire. For firm updates and to be taught extra about Cybin, go to www.cybin.com or comply with the staff on X, LinkedIn, YouTube and Instagram.
View supply model on businesswire.com: https://www.businesswire.com/information/house/20240924826591/en/
Investor & Media Contact:
Gabriel Fahel
Chief Authorized Officer
Cybin Inc.
1-866-292-4601
irteam@cybin.com “ or “ media@cybin.com
Supply: Cybin Inc.
